Access to Company’s Data Clause Samples
The 'Access to Company’s Data' clause defines the rights and limitations regarding a party’s ability to view, use, or retrieve data owned or controlled by the company. Typically, this clause outlines who may access specific types of data, under what circumstances, and for what purposes, such as for service delivery, audits, or compliance checks. For example, it may permit a vendor to access certain operational data only as needed to fulfill contractual obligations, while restricting access to sensitive or confidential information. The core function of this clause is to protect the company’s data assets by clearly delineating permissible access, thereby reducing the risk of unauthorized use or data breaches.
Access to Company’s Data. CyDex shall have the right to reference and utilize all toxicology/safety and other relevant scientific data developed on Captisol alone (and not in conjunction with a Licensed Product) by Company, its Sublicensees or Affiliates, at no cost to CyDex. Upon request by CyDex, Company shall either provide CyDex, at CyDex’s sole expense, with a copy of all such data or shall make such data accessible to CyDex at times and locations reasonably agreeable to CyDex and Company subject to the provisions of Section 8.
Access to Company’s Data. CyDex shall have the right to reference and utilize all toxicology/safety and other relevant scientific data developed on Captisol alone (and not in conjunction with a product formulation) by Company, its Sublicensees or Affiliates in connection with CyDex’s development and commercialization of Captisol or compounds, at no cost to CyDex. Upon request by CyDex, Company shall either provide CyDex with a copy of all such data or shall make such data accessible to CyDex at such times and locations mutually agreed upon by the parties. Portions of this Exhibit, indicated by the ▇▇▇▇ “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.